List of Excipients in Branded Drug ZYMAXID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	BENZALKONIUM CHLORIDE
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	EDETATE DISODIUM
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	HYDROCHLORIC ACID
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	SODIUM CHLORIDE
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	SODIUM HYDROXIDE
Allergan Inc	ZYMAXID	gatifloxacin	0023-3615	WATER

ZYMAXID Excipient Strategy and Commercial Opportunities in Gatifloxacin Ophthalmic Solutions

Last updated: August 9, 2026

ZYMAXID is a 0.5% gatifloxacin ophthalmic solution approved for bacterial conjunctivitis. Its commercial formulation uses a conventional multidose-preserved design with benzalkonium chloride, disodium edetate, glycerin and purified water. The strongest opportunities are not based on new chemical patents. They are based on preservative-free delivery, ocular-surface tolerability, packaging differentiation, manufacturing efficiency and potential 505(b)(2) positioning.

What is ZYMAXID and what excipients does it contain?

ZYMAXID contains gatifloxacin at 5 mg/mL, equivalent to a 0.5% ophthalmic solution. The labeled indication is the treatment of bacterial conjunctivitis caused by susceptible organisms.[1]

ZYMAXID formulation profile

Attribute	ZYMAXID profile
Active ingredient	Gatifloxacin
Strength	0.5%, 5 mg/mL
Route	Topical ophthalmic
Dosage form	Sterile ophthalmic solution
Preservative	Benzalkonium chloride, 0.005%
Chelating agent	Disodium edetate
Tonicity or bulking agent	Glycerin
Vehicle	Purified water
pH adjustment	Hydrochloric acid and/or sodium hydroxide, according to labeling
Primary commercial format	Multidose ophthalmic bottle
FDA application	NDA 022057
Approval year	2009
Regulatory category	Small-molecule ophthalmic drug

The excipient system is functional rather than formulation-intensive. Benzalkonium chloride provides antimicrobial preservation for a multidose container. Disodium edetate can improve preservative performance by binding trace metal ions and may support chemical stability. Glycerin contributes to tonicity and product feel. Water is the vehicle, while acid or base is used for pH adjustment.[1]

What is the excipient strategy behind ZYMAXID?

The ZYMAXID strategy prioritizes low-cost sterile manufacturing and multidose convenience. The formulation does not rely on a complex suspension, emulsion, nanosystem or controlled-release platform.

Benzalkonium chloride and multidose economics

Benzalkonium chloride at 0.005% permits use of a multidose bottle without requiring single-use unit-dose packaging. That design reduces packaging material, filling operations, shipping volume and pharmacy handling costs.

The tradeoff is ocular-surface exposure. Repeated benzalkonium chloride administration has been associated with epithelial toxicity, tear-film disruption and tolerability concerns, particularly in patients with chronic ophthalmic treatment or compromised ocular surfaces.[2] ZYMAXID is generally used for a short anti-infective course, which limits cumulative exposure compared with chronic glaucoma medicines.

Disodium edetate as a support excipient

Disodium edetate is not the primary antimicrobial agent. Its commercial value is support functionality:

• Binding trace metals that can catalyze degradation.
• Supporting preservative performance.
• Helping control formulation robustness during storage.
• Maintaining a relatively simple aqueous system.

Because the excipient is familiar in ophthalmic products, it presents limited regulatory novelty but also limited development risk.

Glycerin and ocular comfort

Glycerin contributes to tonicity and may improve the sensory profile of the solution compared with a formulation that relies only on sodium chloride or a strongly buffered system. It does not create meaningful intellectual-property differentiation by itself.

pH and osmolality control

For an ophthalmic solution, pH, osmolality, buffer capacity, viscosity and drop size affect tolerability and product performance. A commercial follow-on product must control these variables tightly even when it uses the same active ingredient and nominal strength as ZYMAXID.

The principal formulation-development objective is therefore not to create a novel excipient platform. It is to achieve:

1. Chemical and microbiological stability.
2. Acceptable ocular comfort.
3. Equivalent or comparable drug delivery.
4. Reliable sterility through shelf life.
5. A manufacturable drop size and container-closure system.

What formulations are protected by ZYMAXID patents?

The commercially relevant protection for ZYMAXID is likely to be limited because the product is an established small-molecule ophthalmic solution with an approval dating to 2009. The basic gatifloxacin ophthalmic solution formulation is no longer an attractive area for broad composition-of-matter exclusivity.

Patent and exclusivity position

Protection category	ZYMAXID assessment
Gatifloxacin composition of matter	Expired or commercially exhausted for U.S. generic purposes
Original ophthalmic formulation	Any relevant term would require confirmation in the current Orange Book and patent records
Method of treatment	Potentially narrow and likely commercially weak relative to generic substitution
Excipient composition	Limited differentiation from conventional ophthalmic solutions
Container-closure system	Possible device or packaging claims, but unlikely to block the active ingredient broadly
FDA new-drug exclusivity	Any initial exclusivity from the 2009 approval would have expired
Biosimilar exclusivity	Not applicable

The FDA Orange Book should be used to confirm current listed patents and patent delisting status for NDA 022057.[3] The practical competitive question is whether any unexpired patent is listed against the product and whether it covers a formulation or use that a generic applicant would need to avoid. A conventional generic gatifloxacin ophthalmic solution would usually compete primarily on FDA approval, supply reliability, wholesaler access and price.

When did ZYMAXID lose exclusivity?

ZYMAXID’s initial FDA approval occurred in 2009. Any three-year regulatory exclusivity associated with a qualifying new clinical investigation would have expired no later than 2012, assuming the approval did not receive a different statutory exclusivity period.[1,4]

Gatifloxacin itself was approved in other dosage forms before ZYMAXID. As a result, the 2009 ophthalmic approval did not create a new chemical entity exclusivity period for gatifloxacin. Pediatric exclusivity, if granted, would have added six months to an otherwise active exclusivity period, but it would not preserve commercial exclusivity more than a decade after approval.

What is the Orange Book status of ZYMAXID?

ZYMAXID is associated with FDA NDA 022057 and the active ingredient gatifloxacin. Orange Book status should be evaluated across three fields:

• The reference listed drug designation.
• Any active patent listings.
• Any therapeutic-equivalence codes for approved generic versions.

A generic applicant would normally assess whether its product can be submitted through an ANDA referencing the listed drug or whether formulation differences support a 505(b)(2) strategy. For a straightforward gatifloxacin ophthalmic solution, the ANDA route is generally the more economical pathway if the product meets the applicable sameness and bioequivalence requirements.[3,5]

Are Paragraph IV challenges relevant to ZYMAXID?

Paragraph IV risk is likely limited for a legacy product unless an unexpired patent remains listed. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed. If no relevant unexpired patent is listed, a generic applicant would not need to use Paragraph IV as the principal certification.

The commercial importance of a Paragraph IV strategy depends on four factors:

Factor	Impact on ZYMAXID
Listed patent remaining	Determines whether a Paragraph IV filing is available
Patent expiration	Determines launch timing
First-filer economics	Potential 180-day exclusivity can affect generic value
Litigation probability	Depends on patent scope and branded sales

Because ZYMAXID is an older ophthalmic anti-infective, the economic case for expensive patent litigation is weaker than for a high-revenue chronic medicine. A challenger would generally prefer a low-cost ANDA strategy unless a listed patent creates a meaningful launch barrier.

Which companies are challenging ZYMAXID?

The relevant challengers are manufacturers of FDA-approved gatifloxacin ophthalmic solutions rather than biosimilar developers. Gatifloxacin is a conventional small molecule, so the product is subject to the generic drug pathway, not the biosimilar pathway.

The competitive field may include:

• Generic ophthalmic manufacturers.
• Contract development and manufacturing organizations.
• Regional suppliers seeking U.S. ANDA approval.
• Branded-generic companies using preservative-free packaging.
• Ophthalmic companies with existing sterile-fill capacity.

Current applicant and approval status should be verified through FDA’s Drugs@FDA database and the Orange Book because approved products, marketing status and corporate ownership can change.[3,5]

What commercial opportunities exist in ZYMAXID excipients?

The most credible opportunities involve excipient replacement or packaging redesign rather than adding a new excipient to the existing preserved solution.

1. Preservative-free gatifloxacin

A preservative-free product could address concerns about benzalkonium chloride exposure. Commercial formats could include:

• Unit-dose blow-fill-seal ampoules.
• Multidose bottles with antimicrobial container technology.
• One-way valve systems.
• Preservative-free multidose dispensing systems.

A preservative-free formulation would carry higher packaging and filling costs. Its commercial value would depend on whether the product can command a premium in ophthalmology channels or obtain preferential use in patients with ocular-surface disease.

2. Alternative preservatives

Potential alternatives include polyquaternium-based systems, stabilized oxychloro complexes and other ophthalmic preservatives used in marketed products. Each alternative creates a new safety and stability package. The development burden includes antimicrobial effectiveness testing, extractables and leachables, ocular tolerability and container-closure compatibility.

An alternative-preserved product is less differentiated than a preservative-free product because it retains the core issue of repeated preservative exposure. It may still offer value if it improves tolerability or reduces preservative concentration.

3. Improved multidose delivery

Container design can produce a practical commercial advantage without materially changing the formulation. Opportunities include:

• Smaller drop volumes that reduce drug waste.
• Better one-handed dispensing.
• Reduced bottle residual volume.
• Tamper-evident packaging.
• Improved microbial ingress protection.
• Unit-dose adherence packs for short treatment courses.

A smaller drop may reduce runoff and improve patient acceptance, but the developer must demonstrate consistent delivered volume and drug content throughout bottle use.

4. Ocular-comfort optimization

A follow-on product could optimize glycerin, buffering, tonicity or pH to reduce stinging while maintaining gatifloxacin solubility and stability. This opportunity is technically plausible but commercially sensitive. A formulation that differs materially from the reference product may require additional clinical or regulatory justification.

5. Combination products

A gatifloxacin-steroid combination could target postoperative inflammation and infection, but it would be a distinct product strategy. Combination development would face clinical, labeling and safety requirements that do not apply to a simple gatifloxacin generic. It could also compete with established antibiotic-steroid ophthalmic products.

How strong is the patent estate for ZYMAXID?

The patent estate appears commercially weaker than estates built around novel ophthalmic delivery systems. The likely blocking value of the original formulation is limited because it uses standard excipients and a conventional aqueous solution.

Patent-strength assessment

Patent category	Commercial strength
Gatifloxacin molecule	Very low for new U.S. entry
Conventional aqueous solution	Low
Benzalkonium chloride preservation	Low unless narrowly claimed in a specific formulation
Preservative-free delivery	Moderate opportunity for new claims
Specialized bottle or valve	Moderate, but design-around risk is high
Manufacturing process	Moderate if it produces a measurable stability or sterility advantage
Method of treating conjunctivitis	Low to moderate, depending on claim scope
Combination therapy	Potentially moderate, but requires separate clinical support

The strongest new IP opportunity would likely involve a defined preservative-free system, container-closure architecture, improved stability profile, reduced drop size or manufacturing process that produces a differentiated product. Such claims would need to be drafted around measurable technical performance rather than the generic concept of using gatifloxacin in an ophthalmic solution.

What manufacturing and IP barriers affect generic launch?

Sterile ophthalmic manufacturing is the main operational barrier. A company needs validated aseptic processing or terminal sterilization capability, suitable ophthalmic filling equipment, environmental controls and container-closure testing.

Key manufacturing barriers

• Sterile filtration and aseptic filling.
• Low-bioburden raw-material control.
• Uniform gatifloxacin concentration.
• Control of particulate matter.
• Preservative effectiveness over shelf life.
• Container-closure integrity.
• Drop-volume consistency.
• Extractables and leachables evaluation.
• Stability under labeled storage conditions.
• Reliable commercial-scale supply.

The formulation itself is relatively simple. The risk lies in execution, validation and regulatory documentation.

What generic launch scenarios exist for ZYMAXID?

Scenario 1: Standard preserved ANDA

A generic company launches a multidose gatifloxacin 0.5% solution using a formulation close to the reference product. This is the lowest-cost and fastest commercial route, but it creates heavy price competition.

Scenario 2: Preservative-free premium generic

A company launches a preservative-free product in unit-dose or advanced multidose packaging. This strategy supports higher pricing and differentiation but requires greater packaging investment and may require a different regulatory pathway depending on formulation and device differences.

Scenario 3: Institutional and surgical-channel product

A supplier targets hospitals, ambulatory surgery centers and ophthalmology practices with reliable supply, unit-dose packaging and procurement pricing. The value proposition is operational rather than patent-based.

Scenario 4: Regional licensing

A company with a sterile ophthalmic platform could license a gatifloxacin product to a regional pharmaceutical business. The most attractive licensee would already have ophthalmology sales infrastructure and a registered sterile manufacturing site.

How does ZYMAXID compare with other ophthalmic antibiotics?

Product type	Active ingredient	Preservative-free opportunity	Generic pressure	Differentiation potential
ZYMAXID	Gatifloxacin 0.5%	High	High	Moderate through packaging
Moxifloxacin ophthalmic solution	Moxifloxacin 0.5%	High	High	Moderate
Ofloxacin ophthalmic solution	Ofloxacin 0.3%	Possible	High	Low
Tobramycin ophthalmic solution	Tobramycin 0.3%	Possible	High	Low
Besifloxacin ophthalmic suspension	Besifloxacin 0.6%	Formulation-dependent	Moderate	Higher because of suspension and brand positioning

Moxifloxacin is a direct commercial comparator in the fluoroquinolone ophthalmic category. A gatifloxacin product must usually compete on price, availability, formulary status or tolerability rather than molecular novelty.

What is the revenue exposure for a ZYMAXID follow-on product?

Revenue potential is constrained by the short treatment duration, generic competition and low switching costs among topical ophthalmic antibiotics. The most attractive segments are:

• Preservative-sensitive patients.
• Ophthalmology practices seeking unit-dose products.
• Hospitals and surgery centers.
• Markets with limited access to branded fluoroquinolones.
• Private-label and distributor channels.
• Products bundled with broader ophthalmology portfolios.

A standard generic is likely to be a volume and procurement business. A preservative-free or delivery-enhanced product offers better margin potential but requires clinical, packaging and commercial investment.

Key Takeaways

• ZYMAXID is a 0.5% gatifloxacin ophthalmic solution approved in 2009 under NDA 022057.
• Its labeled excipient system uses benzalkonium chloride, disodium edetate, glycerin and purified water.
• The core formulation has limited apparent differentiation and is unlikely to support broad new patent protection.
• Gatifloxacin is a small molecule, so biosimilar risk does not apply.
• The main generic route is an ANDA, subject to current Orange Book and FDA requirements.
• The strongest commercial opportunity is a preservative-free or delivery-optimized product.
• Sterile manufacturing, container-closure integrity and preservative effectiveness are the main technical barriers.
• A standard preserved generic is likely to face significant price competition.
• A premium product requires a clear benefit in ocular tolerability, packaging convenience or institutional procurement.

FAQs

Is ZYMAXID preservative-free?

No. The labeled formulation contains benzalkonium chloride at 0.005%.[1]

Can benzalkonium chloride be removed from a ZYMAXID generic?

Yes, a developer can pursue a preservative-free formulation, but the regulatory pathway, packaging system and supporting comparability data must be evaluated for the specific product design.

Does ZYMAXID have biosimilar competition?

No. Gatifloxacin is a small-molecule active ingredient regulated through generic drug pathways rather than the biosimilar framework.

Is a ZYMAXID formulation patent valuable for licensing?

A conventional preserved aqueous solution has limited licensing value. A formulation patent covering preservative-free multidose delivery, improved stability, reduced drop size or a proprietary container system would have greater commercial potential.

What is the best commercial positioning for a new gatifloxacin ophthalmic product?

The strongest positioning is a preservative-free, low-waste or institutionally efficient product supported by reliable sterile supply. A standard multidose generic would compete mainly on price and availability.

References

1. U.S. Food and Drug Administration. (2009). ZYMAXID (gatifloxacin ophthalmic solution) prescribing information. NDA 022057.

2. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.

4. U.S. Food and Drug Administration. (2024). Exclusivity and patent information in FDA drug approval records.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.